Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.40 |
| ▸ | PGR | P06401 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.40 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.40 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.40 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CHRNA10 | Q9GZZ6 | 1/20 | 0.40 |
| ▸ | CHRNA9 | Q9UGM1 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | GALR3 | O60755 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL71658 | 0.79 | ALDH1A1 (0.46) | ALDH1A1CHRM5CHRM1CHRM3PGR | |
| SCHEMBL3683181 | 0.77 | ALDH1A1 (0.44) | ALDH1A1CHRM5CHRM1CHRM3PGR | |
| SCHEMBL27734433 | 0.76 | ALDH1A1 (0.43) | ALDH1A1CHRM5CHRM1CHRM3PGR | |
| SCHEMBL515652 | 0.75 | ALDH1A1 (0.53) | ALDH1A1TSHR | |
| SCHEMBL11791320 | 0.74 | ALDH1A1 (0.46) | ALDH1A1CHRM5CHRM1CHRM3PGR | |
| SCHEMBL1807366 | 0.72 | ALDH1A1 (0.40) | ALDH1A1CHRM5CHRM1CHRM3PGR | |
| SCHEMBL4229823 | 0.72 | ALDH1A1 (0.48) | ALDH1A1CHRM5CHRM1CHRM3PGR | |
| SCHEMBL2635944 | 0.71 | ALDH1A1 (0.54) | ALDH1A1CHRM5CHRM1CHRM3PGR | |
| SCHEMBL16672248 | 0.71 | ALDH1A1 (0.39) | ALDH1A1CHRM5CHRM1CHRM3PGR | |
| SCHEMBL29221297 | 0.71 | ALDH1A1 (0.39) | ALDH1A1CHRM5CHRM1CHRM3PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6943183-B2 | 5-substituted tetralones as inhibitors of ras farnesyl transferase | PFIZER INC (US) | 2005-09-13 | — | — | US | disclosed |
| US-20040044057-A1 | 5- substituted tetralones as inhibitors of ras farnesyl trransferase | WARNER-LAMBERT COMPANY | 2004-03-04 | — | — | US | disclosed |
| EP-1276725-A2 | 5-SUBSTITUTED TETRALONES AS INHIBITORS OF RAS FARNESYL TRANSFERASE | WARNER-LAMBERT COMPANY (US) | 2003-01-22 | — | — | EP | disclosed |
| US-6352994-B2 | NERVOUS SYSTEM DISORDERS; PSYCHOLOGICAL DISORDERS | MERCK SHARP & DOHME LIMITED (GB) | 2002-03-05 | — | — | US | disclosed |
| WO-2001079180-A2 | 5-SUBSTITUTED TETRALONES AS INHIBITORS OF RAS FARNESYL TRANSFERASE | WARNER-LAMBERT COMPANY (US) | 2001-10-25 | — | — | WO | disclosed |
| US-20010018438-A1 | Substituted 1H-pyridinyl-2-ones as GABAA alpha 2/3 ligands | MERCK SHARP & DOHME LIMITED | 2001-08-30 | — | — | US | disclosed |
| EP-0652218-B1 | Heterocyclic compounds, their production and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2001-07-11 | — | — | EP | disclosed |
| US-6200982-B1 | USEFUL IN THERAPY OF DELETERIOUS MENTAL STATES | MERCK & DOHME LIMITED (GB) | 2001-03-13 | — | — | US | disclosed |
| US-5585385-A | USEFUL IN TREATING DISORDERS OF MICTURITION; ADMINISTERING TO INHIBIT PLASMA EXTRAVASATION | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-12-17 | — | — | US | disclosed |
| EP-0652218-A1 | Heterocyclic compounds, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1995-05-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044057-A1 | 5- substituted tetralones as inhibitors of ras farnesyl trransferase | PTAR1, FNTA, GGPS1 | ALDH1A1 578/4885CHRM5 4733/4885CHRM1 4709/4885 |
| US-20010018438-A1 | Substituted 1H-pyridinyl-2-ones as GABAA alpha 2/3 ligands | GABRB2, GABRB3, GABRB1 | ALDH1A1 484/4885CHRM5 418/4885CHRM1 313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.